journal article·2013-06

Evaluation of biotinylated magnetic nanoparticles for tumour imaging

Ram Prakash Chauhan, Rashi Mathur, Gurjaspreet Singh, Narmada Bag, Sweta Singh, Krishna Chuttani, B. S. Hemanth Kumar, Satyam K. Agrawal, Anil K. Mishra

Journal of Materials Science· Volume 48· Issue 11
Publisher page

Abstract

Target-specific nanoparticles with good stability, dispersibility and targeting properties are very desirable for in vivo applications like diagnosis and therapy. In this work, the potential of covalently biotinylated magnetic nanoparticles for targeting tumours has been analysed by various in vitro and in vivo studies. For quantitatively estimating the amount of biotin bound to the surface of magnetic nanoparticles, 4-Hydroxyazobenzene-2-carboxylic acid dye was used. Varying the pH conditions changes, the mean size and zeta potential and transverse relaxivity slightly, affects the contrast enhancing capability of the synthesized biotinylated magnetic nanoparticles minimally. Cytotoxicity of the synthesized nanoconjugate was analysed in two different cell lines HeLa and A549 by using sulpho-rhodamine B assay and tumour cell-targeting capability was analysed in HeLa cell lines by using confocal microscopy. The results of cytotoxicity analysis combined with intracellular uptake, biodistribution and gamma scintigraphy prove the tumour-targeting potential of the synthesized biocompatible biotinylated magnetic nanoparticle conjugate.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (49)

Show source-provided references
1. Corot C, Robert P, Idee JM, Port M (2006) Adv Drug Deliv Rev 58:147110.1016/j.addr.2006.09.013 ↗
2. Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI (2008) ACS Nano 2:889–89610.1021/nn800072t ↗
3. Lee HS, Kim EH, Shao H, Kwak BK (2005) J Magn Magn Mater 293:102–10510.1016/j.jmmm.2005.01.049 ↗
4. Xu C, Sun S (2009) Dalton Trans 7:5583–559110.1039/b900272n ↗
5. Huber DL (2005) Small 1:482–50110.1002/smll.200500006 ↗
6. Mikhaylova M, Kim DK, Bobrysheva N, Osmolowsky M, Semenov V, Tsakalakos T, Muhammed M (2004) Langmuir 20:2472–247710.1021/la035648e ↗
7. Jain R (1996) Science 271:1079–108010.1126/science.271.5252.1079 ↗
8. Jain R (1987) Cancer Metastasis Rev 6:559–59310.1007/BF00047468 ↗
9. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK (1998) Proc Natl Acad Sci 95:4607–461210.1073/pnas.95.8.4607 ↗
10. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW (2009) Nano Lett 9:1909–191510.1021/nl900031y ↗
11. Maeda H (2001) Adv Enzyme Regul 41:189–20710.1016/S0065-2571(00)00013-3 ↗
12. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) J Control Release 65:271–28410.1016/S0168-3659(99)00248-5 ↗
13. Wunderbaldinger P, Josephson L, Weissleder R (2002) Bioconjug Chem 13:264–26810.1021/bc015563u ↗
14. Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W (1998) Magn Reson Med 40:236–24210.1002/mrm.1910400209 ↗
15. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L (2005) Nat Biotechnol 23:1418–142310.1038/nbt1159 ↗
16. Bonnemain B (1998) J Drug Target 6:167–17410.3109/10611869808997890 ↗
17. Wang YX, Hussain SM, Krestin GP (2001) Eur Radiol 11:2319–233110.1007/s003300100908 ↗
18. Chauhan RP, Singh G, Singh S, Bag N, Patra M, Vadera SR, Mishra AK, Mathur R (2011) Cancer Nano 2:111–12010.1007/s12645-011-0021-9 ↗
19. Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO (2006) Nat Methods 3:391–39610.1038/nmeth875 ↗
20. Sakahara H, Saga T (1999) Adv Drug Deliv Rev 37:89–10110.1016/S0169-409X(98)00101-X ↗
21. Paganelli G et al (1992) Eur J Nucl Med 19:322–32910.1007/BF00177053 ↗
22. Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Brechbiel MW, Choyke PL (2003) Bioconjug Chem 14:1044–104710.1021/bc034064l ↗
23. Tilborg GFV et al (2008) Magn Reson Med 60:1444–145610.1002/mrm.21780 ↗
24. Ashwell G, Harford J (1982) Ann Rev Biochem 51:531–55410.1146/annurev.bi.51.070182.002531 ↗
25. Townsend R, Stahl P (1981) Biochem J 194:209–21410.1042/bj1940209 ↗
26. Toth CA, Thomas P (1992) Hepatology 16:255–26610.1002/hep.1840160137 ↗
27. Schechter B, Silberman R, Arnon R, Wilchek M (1990) Eur J Biochem 189:327–33110.1111/j.1432-1033.1990.tb15493.x ↗
28. Artemov D, Mori N, Ravi R, Bhujwalla ZM (2003) Cancer Res 63:2723–2727
29. Kobayashi H, Sakahara H, Endo K, Hosono M, Yao ZS, Toyama S, Konishi J (1995) Jpn J Cancer Res 86:310–31410.1111/j.1349-7006.1995.tb03056.x ↗
30. Yao Z, Zhang M, Sakahara H, Saga T, Arano Y, Konishi J (1998) J Natl Cancer Inst 90:25–2910.1093/jnci/90.1.25 ↗
31. Yao Z, Zhang M, Sakahara H, Saga T, Nakamoto Y, Sato N, Zhao S, Arano Y, Konishi J (1998) Ann Nucl Med 12:115–11810.1007/BF03164839 ↗
32. Gabius HJ, Engelhardt R, Cramer F (1986) Anticancer Res 6:573–578
33. Lotan R, Raz A (1988) Ann N Y Acad Sci 551:385–38810.1111/j.1749-6632.1988.tb22372.x ↗
34. Jeong JM, Kinuya S, Paik CH, Saga T, Sood VK, Carrasquillo JA, Neumann RD, Reynolds JC (1994) Nucl Med Biol 21:935–94010.1016/0969-8051(94)90082-5 ↗
35. Kobayashi H, Sakahara H, Hosono M, Yao ZS, Toyama S, Endo K, Konishi J (1994) J Nucl Med 35:1677–1684
36. Hama Y, Urano Y, Koyama Y, Kamiya M, Bernardo M, Paik RS, Krishna MC, Choyke PL, Kobayashi H (2006) Neoplasia 8:607–61210.1593/neo.06268 ↗
37. Lee SJ, Jeong JR, Shin SC, Kim JC, Kim JD (2004) J Magn Magn Mater 282:147–15010.1016/j.jmmm.2004.04.035 ↗
38. Bautista MC, Miguel OB, Morales MP, Serna CJ, Verdaguer SV (2005) J Magn Magn Mater 293:20–2710.1016/j.jmmm.2005.01.038 ↗
39. Xu Z, Liu Q, Finch JA (1997) Appl Surf Sci 120:269–27810.1016/S0169-4332(97)00234-1 ↗
40. Ma M, Zhang Y, Yu W, Shen H, Zhang H, Gu N (2003) Coll Surf A Physicochem Eng Asp 212:219–22610.1016/S0927-7757(02)00305-9 ↗
41. Yamaura M, Camilo RL, Sampaio LC, Macedo MA, Nakamura M, Toma HE (2004) J Magn Magn Mater 279:210–21710.1016/j.jmmm.2004.01.094 ↗
42. Hofstetter H, Morpurgo M, Hofstetter O, Bayer EA, Wilchek M (2000) Anal Biochem 284:354–36610.1006/abio.2000.4617 ↗
43. Keepers YP, Pizao PE, Peters GJ, Otte JA, Winograd B, Pinedo HM (1991) Eur J Cancer 27:897–90010.1016/0277-5379(91)90142-Z ↗
44. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) J Natl Cancer Inst 82:1107–111210.1093/jnci/82.13.1107 ↗
45. Sonvico F, Mornet S, Vasseur S, Dubernet C, Jaillard D, Degrouard J, Hoebeke J, Duguet E, Colombo P, Couvreur P (2005) Bioconjug Chem 16:1181–118810.1021/bc050050z ↗
46. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M (1995) Adv Drug Deliv Rev 16:321–33410.1016/0169-409X(95)00033-4 ↗
47. Sun C, Lee JSH, Zhang M (2008) Adv Drug Deliv Rev 60:1252–126510.1016/j.addr.2008.03.018 ↗
48. Rosebrough SF (1993) Nucl Med Biol 20:663–66810.1016/0969-8051(93)90037-U ↗
49. Salem AK, Rose F, Oreffo R, Yang X, Davies MC, Mitchell JR, Roberts CJ, Trenkic SS, Tendler S, Williams PM, Shakesheff KM (2003) Adv Mater 15:210–21310.1002/adma.200390047 ↗